Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally produced in the L-cells of the small intestine and colon in response to food intake. GLP-1 receptor agonists (GLP-1 RAs) are a class of peptide therapies that mimic this hormone's actions at its receptor, producing effects that include enhanced insulin secretion, suppressed glucagon release, slowed gastric emptying, and reduced appetite. The class now includes multiple approved agents — liraglutide, semaglutide, dulaglutide, and tirzepatide (as a dual agonist) — and has transformed the clinical landscape of metabolic medicine over the past decade.
The Science Behind GLP-1
Native GLP-1 has a circulating half-life of only 1–2 minutes, rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonist peptides are engineered to resist DPP-4 degradation, extending activity to hours or days. Importantly, GLP-1 receptors are expressed not only in the pancreas but in the cardiovascular system, kidneys, liver, lungs, and brain — which explains the broad systemic effects observed in clinical trials beyond blood sugar alone.
Research has identified GLP-1 receptor expression in key hypothalamic nuclei and brainstem regions involved in energy homeostasis and reward processing. GLP-1 receptor agonism in the central nervous system reduces hedonic eating behavior and modulates dopamine signaling — providing a mechanistic basis for reduced food cravings observed clinically.
The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) demonstrated statistically significant reductions in major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, establishing GLP-1 RAs as a class with pleiotropic cardiovascular benefits beyond glycemic control.
Different Agents, Different Profiles
- Liraglutide (Victoza/Saxenda): Daily injection; first GLP-1 RA approved for weight management.
- Semaglutide (Ozempic/Wegovy): Weekly injection; substantially greater weight reduction than liraglutide in head-to-head data.
- Dulaglutide (Trulicity): Weekly injection; strong cardiovascular outcomes data (REWIND trial).
- Tirzepatide (Mounjaro/Zepbound): Weekly injection; dual GIP/GLP-1 agonist with superior weight-loss outcomes to single GLP-1 agents in trials.
Who May Be Evaluated for GLP-1 Therapy
Clinical guidelines from organizations including the American Diabetes Association (ADA) and the Obesity Society suggest considering GLP-1 RAs in adults with type 2 diabetes requiring glycemic management, and in adults with obesity or overweight with at least one weight-related comorbidity. A prescribing physician evaluates each patient's complete medical history, current medications, contraindications, and goals before determining appropriateness.
References
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
- Kanoski SE, et al. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885-895.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).